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Prediction of subsequent leukemia-free survival (LFS) and chronic graft-versus-host disease (GVHD) in adults
with acute leukemia who survived at least 1 year after allogeneic hematopoietic cell transplantation is
difﬁcult. We analyzed 3339 patients with acute myeloid leukemia and 1434 patients with acute lymphoblastic
leukemia who received myeloablative conditioning and related or unrelated stem cells from 1990 to 2005.
Most clinical factors predictive of LFS in 1-year survivors were no longer signiﬁcant after 2 or more years. For
acute myeloid leukemia, only disease status (beyond ﬁrst complete remission) remained a signiﬁcant adverse
risk factor for LFS 2 or more years after transplantation. For lymphoblastic leukemia, only extensive chronic
GVHD remained a signiﬁcant adverse predictor of LFS in the second and subsequent years. For patients
surviving for 1 year without disease relapse or extensive chronic GVHD, the risk of developing extensive
chronic GVHD in the next year was 4% if no risk factors were present and higher if noncyclosporine-based
GVHD prophylaxis, an HLA-mismatched donor, or peripheral blood stem cells were used. Estimates for
subsequent LFS and extensive chronic GVHD can be derived for individual patients or populations using an
online calculator (http://www.cibmtr.org/LeukemiaCalculators). This prognostic information is more relevant
for survivors than estimates provided before transplantation.
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Results of hematopoietic cell transplantation (HCT) are
traditionally presented as overall survival, leukemia-freeedgments on page 1604.
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13.08.013survival (LFS), and transplant-related mortality starting
from the time of HCT. The risk of relapse and mortality is
highest early after HCT and then declines with time; thus,
many prognostic factors that are strongly correlated with
early LFS may lose their relevance the longer a patient
survives in remission.
Survivorship studies demonstrated that 2- to 5-year
survivors have an estimated 80% to 95% chance of surviving
5 to 15 years,1-5 with patients age 45 years or older and thoseTransplantation.
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survival.2,4,5 It is difﬁcult, however, to use this information to
counsel individual patients about future risks of relapse and
treatment-related mortality, especially when patients ask,
a year or more after their HCT, about their prognosis. To
answer this question, one needs access to updated prog-
nostic estimates, speciﬁc to the patient’s disease, type of
transplant, duration of survival since HCT, and current
condition. This information is important for patients, family
members, and others to have realistic expectations. A patient
who is told he or she has an extremely poor prognosis before
transplant but who survives at least 1 year should be given
an updated prognostic estimate. Conversely, all patients
should be aware of a continued risk of higher mortality
than the general population, especially if this encourages
compliance with medical follow-up and recommended
preventive care.
METHODS
The cohort consisted of all patients aged 18 years or older who had a ﬁrst
myeloablative allogeneic transplant for acute myeloid leukemia (AML) or
acute lymphoid leukemia (ALL) between 1990 and 2005, reported to the
Center for International Blood and Marrow Transplant Research (CIBMTR),
and who survived at least 1 year without relapse of their disease. Only
centers with 80% completeness index at 4 years (3 years of follow-up for
more than 80% of 1-year survivors) were included to minimize reporting
bias. Patients with syngeneic twin, cord blood, or haploidentical donors or
who received reduced-intensity/nonmyeloablative conditioning transplants
were excluded. Patients receiving reduced-intensity/nonmyeloablative
conditioning were excluded so we could focus on a more homogeneous
patient population where we could assume a certain level of organ func-
tioning. Comorbidity data were not collected by the CIBMTR before 2008
and would be especially important in a study of reduced-intensity/
nonmyeloablative conditioning.
LFS, deﬁned as survival without relapse, was chosen as the primary
endpoint because there is only a 3% absolute survival difference between
survival and LFS for patients with acute leukemia. In addition, the inclusion
criteria at each landmark are based on LFS. Patients were censored at time of
last follow-up. We conducted a similar analysis for extensive chronic graft-
versus-host disease (GVHD), deﬁned according to CIBMTR criteria,6 that
deﬁnes chronic GVHD as GVHD occurring after day 100 and severity as
limited or extensive because the National Institutes of Health criteria are not
yet used in the CIBMTR database.7
Potential clinical variables were current patient age, patient gender,
Karnofsky performance status at transplant,8 patient race, donorerecipient
gender match,9 donor and recipient cytomegalovirus serostatus,10 donor
type, HLA matching,11 graft type, conditioning regimen, GVHD prophylaxis,
use of antithymocyte globulin or Campath, and prior grades II to IV acute
GVHD. Prior extensive chronic GVHD was evaluated as a predictor of
subsequent LFS.
Disease-speciﬁc factors were disease, disease stage, extramedullary
involvement at any time before transplant, cytogenetics, white blood cell
count at diagnosis,12,13 time from ﬁrst complete response to transplant, and
duration of remission. Cytogenetic classiﬁcation was primarily based on the
Southwest Oncology Group/Eastern Cooperative Oncology Group and
Medical Research Council classiﬁcations, with additional classiﬁcation of
speciﬁc abnormalities by other schema if available.14-19 Additional variables
included secondary leukemia (AML only) and time from diagnosis to ﬁrst
complete remission,18 lineage (T versus B versus other), and Philadelphia-
chromosome or BCR-ABL positivity (ALL only). Because of missing data or
low numbers, we could not consider percent bone marrow or peripheral
blood blasts at transplant.20 For AML, we could not consider FAB subtype21,22
or the newer molecular markers such as NPM1, FLT3, CEBPA, and MLL23;
pretransplant ferritin level18; and post-transplant minimal residual disease
assessments.24
Statistical Considerations
Univariate screening of candidate patient and transplant variables was
performed separately for ALL and AML among 1-year leukemia-free survivors,
using 2-year LFS rates as the endpoint. Risk factors signiﬁcant at the .05 level
were then included in a multivariate analysis with stepwise backward selec-
tion at the .01 level of signiﬁcance. The identiﬁed risk factorswere then used at
each subsequent landmark year to predict survival in the subsequent year.
Analyses were based on Poisson regression with additive risk structure.
For multicategory variables, categories with similar risk contributions werepooled for simplicity. A competing risk analysis was not used because the
overwhelming causes of death in the ﬁrst 5 years after transplant are related
to the transplant or underlying malignancy. For the chronic GVHD analysis,
we excluded patients who had received T cell depletion for GVHD prophy-
laxis because they had an extremely low rate of chronic GVHD after 1 year
that would have caused instability and boundary problems in the additive
model. We also excluded patients from the chronic GVHD model if they
developed extensive chronic GVHD before 1 year because we wanted our
prognostic estimates to be valid for patients without prior chronic GVHD.RESULTS
Table 1 shows the characteristics of the 3339 AML and
1434 ALL patients included in the study. Other patients (n ¼
4511) transplanted during the study period were not eligible
for inclusion in the study because of death or relapse during
the ﬁrst year after HCT (n ¼ 3828), lack of follow up (n ¼
301), or transplantation at centers with low completeness
index (n ¼ 382).
LFS for AML patients in this study was 90% at 2 years and
78% at 5 years. For ALL, LFS was 87% at 2 years and 71% at 5
years. Univariate analyses identiﬁed the following factors
signiﬁcantly associated with worse LFS. For AML, these
factors were second or greater remission at transplant,
relapse/refractory disease at transplant, poor-risk cytoge-
netics, tacrolimus-based GVHD prophylaxis, duration of
remission >1 year, more recent year of transplant, donor not
a matched sibling, Karnofsky performance status <90, prior
extensive chronic GVHD, secondary AML, and peripheral
blood stem cell graft. For ALL, these factors were second or
greater remission at transplant, relapse/refractory disease at
transplant, Philadelphia chromosomeepositive, prior acute
GVHD, prior extensive chronic GVHD, donor exposed to
cytomegalovirus, female donor for male patient, Karnofsky
performance status <90, and B cell lineage (Supplementary
Table 1).
Table 2 summarizes the results of the multivariate anal-
ysis, considering P < .05 as signiﬁcant. An online calculator is
available at http://www.cibmtr.org/LeukemiaCalculators to
allow calculation of the personalized probability of disease-
free survival in the subsequent years by entering a patient’s
individual risk factor information. For example, a patient
with AML who has intermediate-risk cytogenetics and is in
second complete remission with a Karnofsky performance
status of 90% to 100% at transplant and who survives for 1
year has a 12.9% chance of relapse or mortality in the next
year.
Table 3 shows how risk factors are additive in calculating
subsequent risk and illustrates the estimated and actual LFS
and conﬁdence intervals for patients with particular
combinations of risk factors. Table 3 also shows the actual LFS
of groups of patients (n > 25) with the particular combina-
tions of risk factors transplanted in 2004 to 2005 to test the
predictive ability of the model in more recently transplanted
patients. Table 4 shows the results for patients transplanted
for ALL. Because the formulas to calculate risks are quite
complicated, use of the online calculator is recommended.
Previous CIBMTR reports have shown that 90% to 95% of
chronic GVHD cases are diagnosed within the ﬁrst year after
HCT.25,26 In our cohort, 89% of all cases of extensive chronic
GVHD were diagnosed within the ﬁrst year, and 8% of cases
were diagnosed between 1 and 2 years. Only 3% of chronic
GVHD developed after 2 years, so the analysis only attempted
to predict onset of chronic GVHD between 1 and 2 years. We
found that patients who survive to 1 year, free of their
original malignancy and without any prior extensive chronic
GVHD, still have a 4% chance of being diagnosed with
Table 1
Characteristics of Patients 18 Years Old Who Underwent Myeloablative
Transplant from 1990 to 2005 for AML or ALL and Were 1-Year Survivors
Characteristics AML ALL
n (%) n (%)
Number of patients 3339 1434
Number of centers 244 228
Age at transplantation, yr, median
(range)
37 (18-69) 29 (18-64)
Recipient age in decades, yr
18-29 977 (29) 746 (52)
30-39 937 (28) 370 (26)
40-49 958 (29) 236 (16)
50þ 467 (14) 82 (6)
Sex
Male 1752 (52) 883 (62)
Female 1587 (48) 551 (38)
Donorerecipient sex match
Male donoremale recipient 1021 (31) 560 (39)
Male donorefemale recipient 832 (25) 303 (21)
Female donoremale recipient 721 (22) 314 (22)
Female donorefemale recipient 745 (22) 247 (17)
Missing 20 (1) 10 (1)
Donorerecipient CMV match
Negative donorenegative recipient 904 (27) 462 (32)
Negative donorepositive recipient 768 (23) 305 (21)
Positive donorepositive recipient 1130 (34) 420 (29)
Positive donorenegative recipient 395 (12) 180 (13)
Missing 142 (4) 67 (5)
Karnofsky score at transplant
<90 Karnofsky 754 (23) 317 (22)
90 Karnofsky 2474 (74) 1076 (75)
Missing 111 (3) 41 (3)
Race/ethnicity of recipient
White 2816 (84) 1191 (83)
African American 70 (2) 31 (2)
Asian 287 (9) 125 (9)
Hispanic 89 (3) 59 (4)
Other 59 (2) 20 (1)
Missing 18 (1) 8 (1)
Disease status at transplant
CR1 1981 (59) 830 (58)
CR2 648 (19) 351 (24)
>CR2 41 (1) 58 (4)
Relapse 383 (11) 118 (8)
Primary induction failure 251 (8) 50 (3)
Missing 35 (1) 27 (2)
Cytogeneticgroups
Good 384 (12) 56 (4)
Intermediate/normal 1832 (55) 596 (42)
Poor risk 334 (10) 353 (25)
Missing 789 (24) 429 (30)
Phþ/BCR-ABLþ
No 722 (50)
Yes 283 (20)
Missing 429 (30)
T lineage vs. B lineage
B lineage 933 (65)
T lineage 241 (17)
Other 148 (10)
Missing 112 (8)
Type of AML
Denovo 2832 (85)
Secondary 415 (12)
Missing 92 (3)
HLA match
HLA-identical sibling 2221 (67) 835 (58)
Other related donor 58 (2) 26 (2)
Well-matched URD 479 (14) 250 (17)
Partially matched URD 328 (10) 190 (13)
Mismatched URD 166 (5) 83 (6)
Missing 87 (3) 50 (3)
Source of stem cell
Bone marrow 2269 (68) 1039 (72)
Peripheral blood 1070 (32) 395 (28)
(continued)
Table 1
(continued)
Characteristics AML ALL
n (%) n (%)
Conditioning regimen based on
distribution
BuþCyother 1410 (42) 184 (13)
TBIþCyBuother 1897 (57) 1243 (87)
BuþFludaraother (no TBI) 32 (1) 7 (<1)
GVHD prophylaxis
Ex vivo T cell depletion 322 (10) 148 (10)
CsAother 2428 (73) 1018 (71)
Tacrolimusother 519 (16) 244 (17)
Other 70 (2) 24 (2)
Chronic GVHD
No chronic GVHD 1560 (47) 648 (45)
Limited GVHD 652 (20) 295 (21)
Extensive GVHD 1105 (33) 487 (34)
Missing 22 (1) 4 (<1)
Acute GVHD grades II-IV
No 2355 (71) 934 (65)
Yes 955 (29) 496 (35)
Missing 29 (1) 4 (<1)
Year of transplant
1990-1993 876 (26) 352 (24)
1994-1997 924 (28) 368 (26)
1998-2001 679 (20) 298 (21)
2002-2005 860 (26) 416 (29)
Median follow-up of survivors, mo
(range)
96 (12-249) 87 (12-240)
CMV indicates cytomegalovirus; CR, complete remission; URD, unrelated
donor; Bu, busulfan; MTX, methotrexate; CsA, cyclosporine; CY, cyclo-
phosphamide; TBI, total body irradiation.
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estimate ranges from 2% to 18% based on risk factors and was
higher if a patient received noncyclosporine-based GVHD
prophylaxis without antithymocyte globulin or Campath,
received peripheral blood, or had a donor other than an HLA-
identical sibling (Table 5).
DISCUSSION
Our results allow updated prognostic estimates to be
calculated for individual patients based on their clinical
characteristics, using a formula derived from an analysis of
thousands of patients. We conclude that most factors
predictive of LFS at the time of and after HCT lose their
impact once patients survive without relapse for 2 or more
years. People with a history of extensive chronic GVHD have
a lower LFS compared with those without chronic GVHD up
to 6 years post-HCT for ALL but not for AML. AML that is in
relapse or refractory at the time of transplant also remains an
adverse prognostic factor even for 5-year disease-free
survivors, but this is not operative in ALL. Conversely, it is
notable that factors such as age and donor type were not
signiﬁcantly predictive of outcome for patients after they had
survived the ﬁrst year.
Overall, the likelihood of subsequent survival is high but
varies depending on certain clinical variables. Many reports
suggest that extensive chronic GVHD is associated with
higher transplant-related mortality and lower survival.
Severity of chronic GVHD according to National Institutes of
Health criteria and continued need for immunosuppression
are also associated with these outcomes, but the CIBMTR
database lacked adequate data to test these hypotheses.27
Using available data, chronic GVHD was an adverse prog-
nostic factor for ALL but not AML. This could be because the
Table 2
Additive Effects on Subsequent 1-Year Event Rates Among AML/ALL Disease-Free Survivors at Various Landmark Times Post-HCT: (a) AML and (b) ALL
(a) AML
1 Year 2 Years 3 Years 4 Years 5 Years
No. at risk 3315 2824 2535 2277 1967
No. of events 434 193 123 61 50
Patient years of follow-up during interval 3012 2677 2403 2133 1776
Background rate for general population* .0027 .0028 .0029 .0031 .0033
N N N N N
Baseline rate for transplanted patients if no risk factors presenty .089 .049 .033 .021 .019
þ Poor risk cytogenetics 334 .087z 267 .033x 238 .020 206 .022 167 .015
þ Second or greater remission at HCT 689 .049z 586 .060k 507 .024x 451 .002 387 .018x
þ Relapse/refractory at HCT 626 .162z 475 .039k 418 .035k 370 .028k 318 .029k
þ Karnofsky performance status <90 at HCT 746 .050z 597 .008 527 .024x 468 .001 412 .010
(b) ALL
1 Year 2 Years 3 Years 4 Years 5 Years
No. at risk 1426 1113 977 867
No. of events 280 92 39 45
Patient years of follow-up during interval 1240 1042 921 1450
Background rate for general population* .0018 .0020 .0020 .0021
N N N N
Baseline rate for transplanted patients if no risk factors presenty .098 .065 .022 .012
þ Philadelphia/BCR-ABLþ 280 .124z 199 .031x 165 .029x 145 .014
þ Second or greater remission at HCT 407 .126z 308 .006 271 .031x 237 .016x
þ Relapse/refractory at HCT 167 .316z 106 .004 93 .001 85 .017
þ Extensive chronic GVHD, past or current 451 .085z 375 .047k 332 .023x 299 .034z
The formula to convert the event rate per person-year (x) into the probability of an event over the year (p) for a single person is p ¼ 1  exponent (x), with x
being the sum of the baseline rate and any additional risk factors. If the event rate is<.2, then the probability of an event is approximately equal to the event rate,
but at greater values of the event rate, the event rate is greater than the probability of an event expressed as a percentage. Values are in bold if p < .05.
* Death rate expected in a general population cohort with similar sex and age distribution, for comparison with the transplanted population.
y Event rate per person-year at risk (¼ approximate probability of death/relapse) in a population of patients transplanted for AML or ALL if no risk factors are
present.
z P < .01.
x P < .2.
k P < .05.
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increased transplant-related mortality was consequently
more inﬂuential on overall survival than in AML.
This analysis has a number of limitations. We used
CIBMTR data, which includes hundreds of centers, so our
results are generalizable but may not reﬂect the practices
and success rates of any particular center. We lacked some
clinical details such as molecular markers, evidence of
minimal residual disease, and chronic GVHD incidence and
severity according to the National Institutes of Health
consensus conference that might have contributed to
reﬁnement of the prognostic estimates. The study population
includes only myeloablative recipients who survived at least
1 year without recurrent disease, and our results are only
applicable to similar patients. The median patient age is
likely lower than in current practice, although age was notTable 3
Examples of 2-Year Estimated and Actual LFS, 95% Conﬁdence Intervals (CIs) for 1-
Risk Factors N Estimated
LFS
95% CI
No risk factors 1408 91.5% 90.1-93.0
Poor-risk cytogenetics 173 83.9% 79.4-88.6
Second or later complete remission 488 87.1% 84.4-89.9
Relapse/refractory at transplant 329 77.9% 74.2-81.7
Karnofsky performance status <90 at transplant 310 87.1% 83.9-90.3
Poor risk cytogenetics þ relapse/refractory 39 71.4% 66.5-76.6
Karnofsky performance status <90 at transplant
þ relapse/refractory
205 74.1% 70.3-78.0
Karnofsky performance status <90 at transplant
þ relapse/refractory þ poor risk cytogenetics
25 67.9% 63.2-73.0a signiﬁcant prognostic factor in the multivariate analysis.
Similar analyses could be performed for the reduced-
intensity and nonmyeloablative approaches once sufﬁcient
numbers of survivors with enough follow-up and comorbidity
data are available. The low number of relapses and deaths in
survivors during the 1-year time periods of analysis may
have also limited the power to identify signiﬁcant prognostic
factors. Transplantation practices are constantly evolving,
and some innovations such as use of tyrosine kinase inhibi-
tors in BCR-ABLepositive ALL may overcome the currently
identiﬁed negative prognostic factors.28 However, many
more patients will need to be accrued to conﬁrm this
hypothesis and provide an estimate of any beneﬁcial effect.
Studies such as ours that require large number of patients to
personalize prognostic estimates will always necessarily lag
behind the newest innovations. The fact that patientsYear AML Survivors, and Observed LFS from the 2 Most Recent Years
Observed LFS
(1990-2005)
95% CI N Recent 2 Years
(2004-2005)
Observed
LFS
95% CI
91.4% 89.9-92.9 170 91.8% 87.5-96.1
83.6% 78.1-89.1 47 84.4% 73.8-95.0
87.2% 84.2-90.2 88 87.4% 80.4-94.4
79.9% 75.5-84.3 40 82.5% 70.7-94.3
89.0% 85.5-92.5 33 87.9% 76.8-99.0
79.1% 66.2-92.0 7 d d
72.1% 65.8-78.4 27 56.6% 36.4-76.8
56.0% 36.5-75.5 3 d d
Table 4
Examples of 2-Year Estimated and Actual LFS, 95% Conﬁdence Intervals (CIs) for 1-Year ALL Survivors, and Observed LFS from the 2 Most Recent Years
Risk Factors N Estimated
LFS
95% CI Observed LFS
(1990-2005)
95% CI N Recent 2 Years
(2004-2005)
Observed
LFS
95% CI
No risk factors 441 90.6% 88.1-93.3 90.5% 87.7-93.3 42 84.6% 73.3-95.9
Philadelphia/BCR-ABLþ 138 80.1% 74.5-86.1 82.9% 76.5-89.3 35 78.7% 64.7-92.7
Second or later complete remission 250 79.9% 75.6-84.5 80.5% 75.5-85.5 37 80.2% 67.0-93.4
Relapse/refractory at transplant 89 66.1% 58.7-74.4 64.4% 54.3-74.5 6 d d
Extensive chronic GVHD, past or current 158 83.2% 78.7-88.1 83.5% 77.7-89.3 34 82.4% 69.6-95.2
Philadelphia/BCR-ABLþ and relapse/refractory at
transplant
22 58.4% 51.1-66.8 54.5% 33.7-75.3 2 d d
Extensive chronic GVHD, past or present and relapse/
refractory at transplant
48 60.7% 53.5-68.9 72.7% 60.0-85.4 9 d d
Extensive chronic GVHD, past or present and relapse/
refractory at transplant and Philadelphia/BCR-ABLþ
9 53.6% 46.8-61.5 d d 0 d d
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had remarkably similar survival rates to the entire cohort
suggests that therapeutic advances may have more of an
impact within the ﬁrst year after transplantation than in later
post-transplant years. Because our study started with 1-year
survivors, our results may not be as susceptible to being
outdated as quickly as other studies that focus on the early
post-transplant period.
Nevertheless, patients and their physicians, as well as
people designing clinical research studies involving the
survivor population, may beneﬁt from results that update
LFS based on the most current patient characteristics,
including the fact that patients have already survived for
some period of time. Patients who enter HCT with multiple
adverse disease factors may beneﬁt from knowing that most
of these poor risk factors lose their potency once a patient
survives 2 or more years after HCT. The public availability of
the online calculators allows patients and physicians to
calculate individualized and current prognostic estimates,
based on the best available data derived from thousands of
patients. They may then apply their own “sensitivity” anal-
yses to incorporate new information, and the calculators can
be formally updated regularly based on more recent cohorts
to reﬂect evolving medical practice.Table 5
Additive Effects on Subsequent 1-Year Probability of Developing Chronic
GVHD Among AML/ALL Disease-Free Survivors at 1 Year
Chronic GVHD* 1 Year
No. at risk 2836
No. of events 127
Patient years of follow-up 2481
N
Baseline rate for transplanted patients if
no risk factors presenty
.019
þ Noncyclosporine-based GVHD prophylaxis
without antithymocyte globulin or Campath
356 .087z
þ Peripheral blood stem cell graft 755 .048z
þ Donor other than HLA-identical sibling 734 .044z
The formula to convert the event rate per person-year (x) into the proba-
bility of an event over the year (p) for a single person is p ¼ 1  exponent
(x), with x being the sum of the baseline rate and any additional risk
factors. If the event rate is <.2, then the probability of an event is approx-
imately equal to the event rate, but at greater values of the event rate, the
event rate is greater than the probability of an event expressed as
a percentage.
* Excluding 384 patients receiving T celledepleted grafts, who experi-
enced 3 events in 347 person years, or .009 events per person year at risk.
y Event rate per person-year at risk (¼ approximate probability of chronic
GVHD) in a population of patients transplanted for acute leukemia if no risk
factors are present.
z P < .01 (values are in bold if P < .05).ACKNOWLEDGMENTS
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Univariate Analyses of Risk Factors for Rate of Mortality þ Relapse During Second-
AML
N Rate Difference (95% CI)
ANC engraftment
<16 days 1439 Ref
16 days 1844 .024 (.052-.003)
Platelet engraftment
<23 days 1215 Ref
23 days 1109 .009 (.043-.025)
Gender
Male 1740 Ref
Female 1575 .008 (.035 - .019)
Donorerecipient gender
Other 2585 Ref
Female/male 716 .009 (.025-.043)
KPS at HCT
90-100 2465 Ref
<90 746 .086 (.048-.125)
Duration of remission
<1 year 382 Ref
1 year 558 .108 (.050-.166)
Extramedullary disease
Absent 2918 Ref
Present 369 .042 (.006-.090)
Stem cell source
Marrow 2252 Ref
PBSC 1063 .034 (.003-.064)
Acute GVHD
Grades 0-I 2347 Ref
Grades II-IV 945 .013 (.018-.043)
Race
White 2797 Ref
Other 501 .012 (.049-.024)
Recipient CMV serostatus
Negative 1292 Ref
Positive 1888 .012 (.016-.040)
Donor CMV serostatus
Negative 1663 Ref
Positive 1517 .000 (.028-.027)
TBI in conditioning
No 1435 Ref
Yes 1880 .000 (.027-.027)
WBC count at diagnosis
<30 2035 Ref
30-100 585 .013 (.048-.022)
>100 267 .017 (.037-.071)
Time from ﬁrst CR to HCT
<6 mo 1557 Ref
6-12 mo 286 .029 (.067-.009)
>12 mo 44 .063 (.130-.004)
Age at transplant
18-29 972 Ref
30-44 1441 .015 (.046-.017)
45-69 902 .035 (.003-.074)
Donor HLA match
HLA-identical sibling 2200 Ref
Well matched 478 .043 (.000-.085)
Other matching 550 .060 (.018-.101)
Cytogenetic risk
Good 383 Ref
Intermediate/normal 1824 .003 (.046-.040)
Poor 334 .072 (.006-.138)
Unknown 774 .000 (.047-.048)
GVHD prophylaxis
Cyclosporin-based 2192 Ref
Tacrolimus-based 411 .063 (.015-.112)
T cell depletion 322 .010 (.036-.057)
Antithymocyte globulin/Campath 338 .024 (.023-.071)
Other 46 .051 (.085-.188)
Disease status at HCT
First remission 1971 Ref
Second remission 648 .048 (.012-.083)Year Post- HCT
ALL
P N Rate Difference (95% CI) P
573 Ref
.09 837 .024 (e.029-.078) .37
469 Ref
.60 547 .046 (e.019-.110) .17
878 Ref
.56 548 016 (070-.038) .56
1105 Ref
.61 313 .135 (.059-.211) .0005
1071 Ref
<.0001 315 .086 (.014-.157) .02
277 Ref
.0003 171 .087 (.036-.209) .16
1085 Ref
.09 325 .006 (.068-.057) .86
1033 Ref
.03 393 .046 (.017-.108) .15
928 Ref
.41 495 .074 (.016-.133) .01
1184 Ref
.51 234 .034 (.042-.110) .38
638 Ref
.41 722 .036 (.019-.090) .20
761 Ref
.98 599 .094 (.037-.151) .001
190 Ref
.99 1236 .073 (.161-.015) .11
.90* 803 Ref .97*
.48 247 .035 (.102-.031) .30
.54 162 .038 (.054-.129) .42
.08* 624 Ref .92*
.13 152 .000 (.074-.075) .99
.07 23 .010 (.176 - .156) .91
.50* 740 Ref .15*
.36 521 .043 (.015-.101) .14
.07 165 .041 (.048-.130) .36
.001* 827 Ref .88*
.05 250 .013 (.061-.087) .73
.005 299 .022 (.086-.043) .52
.32* 55 Ref .76*
.89 595 .035 (.183-.112) .64
.03 352 .018 (.136-.172) .82
.99 424 .048 (.197-.101) .53
.05* 897 Ref .71*
.01 217 .029 (.050-.107) .47
.66 148 .005 (.092-.081) .91
.32 140 .034 (.063-.132) .49
.46 22 .005 (.217-.206) .96
<.0001* 827 Ref <.0001*
.008 349 .105 (.040-.169) .001
(Continued)
Supplementary Table 1
(continued)
AML ALL
N Rate Difference (95% CI) P N Rate Difference (95% CI) P
Remission > second 41 .030 (.117-.058) .50 58 .129 (.023-.281) .10
Relapse/refractory 626 .165 (.119-.212) <.0001 167 .308 (.186-.429) <.0001
AML origin
De novo 2822 Ref Not applicable
Secondary 412 .045 (.000-.091) .05
Chronic extensive GHVD
None 2256 Ref 962 Ref
Prior or current 1026 .051 (.020-.083) .002 451 .099 (.037-.161) .002
Year of transplant
Continuous, per year 3315 .003 (.000-.006) .03 1426 .004 (.002-.010) .17
Philadelphia-BCR/ABL
Negative Not applicable 722 Ref .08*
Positive 280 .102 (.022-.182) .01
Unknown 424 .005 (.063-.053) .86
Time from diagnosis to ﬁrst CR
0-8 wk Not applicable 880 Ref
>8 wk 372 .044 (.018-.106) .16
Type of ALL
T cell Not applicable 240 Ref .003*
B cell 929 .104 (.041-.166) .001
Other 147 .124 (.018-.229) .02
ANC indicates absolute neutrophil count; KPS, Karnofsky performance status; PBPC, peripheral blood progenitor cells; CMV, cytomegalovirus; TBI, total body
irradiation; WBC, white blood cell; CR, complete remission; BCR-ABL, breakpoint cluster region-Abelson gene rearrangement.
* Overall P value.
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